Ami Fadia, an analyst from Needham, reiterated the Buy rating on Axsome Therapeutics (AXSM – Research Report). The associated price target remains the same with $153.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ami Fadia has given his Buy rating due to a combination of factors that highlight Axsome Therapeutics’ potential for significant growth. The company’s recent earnings report showed that both Auvelity and Sunosi sales exceeded expectations, indicating strong market performance. Additionally, Axsome’s broad late-stage pipeline offers promising opportunities for future development and expansion.
Ami Fadia anticipates continued momentum in 2025, driven by the expansion of the sales force, increased payer coverage, and direct-to-consumer advertising for Auvelity in the major depressive disorder market. The upcoming launch of Symbravo and progress in regulatory processes for several assets further support this positive outlook. Key data catalysts, such as clinical data presentations and regulatory submissions, are expected to drive further interest and potential upside for Axsome Therapeutics.
According to TipRanks, Fadia is a 2-star analyst with an average return of 0.0% and a 41.87% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Biogen, and Jazz Pharmaceuticals.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $190.00 price target.